首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
【24h】

Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.

机译:循环内皮祖细胞和CXCR4阳性循环内皮细胞是贝伐单抗的预测标记。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Bevacizumab plus chemotherapy is a standard option in the treatment of metastatic colorectal cancer (mCRC). The aim of this study was to investigate the potential of circulating endothelial cell progenitors (CEPs) and phenotypical circulating endothelial cells (CECs) as surrogate markers of clinical outcome in mCRC patients to identify responders to bevacizumab in combination with chemotherapy. METHODS: A total of 69 patients with measurable mCRC were enrolled in this prospective study. Whole blood samples were analyzed before initiation of treatment and on days 4 and 14. Phenotypical CECs and CEPs were then isolated and enumerated by using flow cytometry. RESULTS: CEP levels of less than 0.04% on day 4 were significantly associated with longer progression-free survival (PFS) and overall survival (OS) (P < .001, P = .002, respectively) as compared with levels of 0.04% or more. In addition, CXCR4-positive CEC levels of less than 20% at baseline were significantly associated with longer PFS and OS as compared other indicators investigated (P < .001, P = .002, respectively). CONCLUSIONS: Levels of CEPs on day 4 and proportion of CXCR4-positive CECs at baseline were correlated with the prognosis of bevacizumab combination chemotherapy, suggesting that these surrogate markers may play a core role in the selection of candidates for bevacizumab treatment.
机译:背景:贝伐单抗联合化疗是转移性结直肠癌(mCRC)治疗的标准选择。这项研究的目的是调查循环内皮细胞祖细胞(CEPs)和表型循环内皮细胞(CECs)作为mCRC患者临床预后指标的潜力,以鉴定贝伐单抗联合化疗的应答者。方法:该前瞻性研究共纳入69例可测量的mCRC患者。在开始治疗之前以及第4天和第14天,对全血样本进行了分析。然后,通过流式细胞术分离并计数了典型的CEC和CEP。结果:CEP在第4天的水平低于0.04%与更长的无进展生存期(PFS)和总体生存期(OS)显着相关(分别为P <.001,P = .002),而水平为0.04%或者更多。此外,与其他调查指标相比,基线时低于20%的CXCR4阳性CEC水平与更长的PFS和OS显着相关(分别为P <.001,P = .002)。结论:第4天的CEP水平和基线时CXCR4阳性CEC的比例与贝伐单抗联合化疗的预后相关,表明这些替代标志物可能在选择贝伐单抗治疗的候选人中起核心作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号